Drug Profile

MDX 2201

Alternative Names: MDX-2201; MDX2201 EBV nanoparticle vaccine; V-350; V350A; V350B

Latest Information Update: 09 Mar 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator ModeX Therapeutics Inc
Developer Merck AG
Class Vaccines; Viral vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I Epstein-Barr virus infections

Most Recent Events

27 Feb 2026 Merck Sharp & Dohme plans a phase II trials for Epstein-Barr virus infections
05 Dec 2024 Phase-I clinical trials in Epstein-Barr virus infections (Prevention) in USA (IM, Injection) (NCT06655324)
08 Mar 2023 MDX 2201 licensed to Merck worldwide

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com